Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro

Clinical trials using kinase inhibitors have demonstrated transient partial responses and disease control in patients with progressive medullary thyroid cancer (MTC). The goal of this study was to identify potential combinatorial strategies to improve on these results using sorafenib, a multikinase...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Koh, Yoon Woo, Shah, Manisha H, Agarwal, Kitty, McCarty, Samantha K, Koo, Bon Seok, Brendel, Victoria J, Wang, Chaojie, Porter, Kyle, Jarjoura, David, Saji, Motoyasu, Ringel, Matthew D
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3717592/
https://ncbi.nlm.nih.gov/pubmed/22109971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-11-0155
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller